Targeted synthetic fibrocyte activating protein compound and application thereof

By introducing urea groups into FAP-binding compounds, the retention time of the tumor site is prolonged and radionuclides are combined, the problem of short retention time of existing FAP-targeted compounds is solved, and the imaging and treatment effect of tumors is improved.

CN118955616AActive Publication Date: 2024-11-15AB RAYBIO THERAPEUTICS CO LTD

Patent Information

Application Number
CN202410873169.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-05-01
Filing Date
2024-07-01
Publication Date
2024-11-15
Estimated Expiration
2044-07-01

AI Technical Summary

Technical Problem

The existing FAP-targeting compounds have a short tumor retention time in vivo, resulting in poor radiotherapy effects and rapid metabolism, affecting the sensitivity of diagnosis and treatment.

Method used

By introducing urea groups into the structure of FAP-bound compounds, the enzyme activity is reduced to prolong the retention time of the compound at the target site, and the uptake and retention amount in the tumor are increased, and radionuclides are combined as nuclide probe drugs for targeting FAP tumors. Imaging and treatment.

Benefits of technology

It effectively improves the retention time and intake of compounds in the tumor site, realizes the integrated diagnosis and treatment of compounds, and improves the effect of tumor imaging and treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118955616A_ABST
    Figure CN118955616A_ABST
Patent Text Reader

Abstract

The invention relates to the field of radiopharmaceuticals, in particular to a targeted binding fibrocyte activating protein compound and application thereof. The FAP binding compound and the metal complex thereof have a brand new chemical structure, so that the compound or the pharmaceutical composition can be applied to diagnosis or treatment of diseases characterized by over-expression of fibroblast activating protein (FAP).
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority to Chinese patent application No. 202410542901.7 filed on May 1, 2024, entitled “A compound targeting fibroblast activation protein (FAP) and its application”, which is incorporated herein by reference in its entirety. Technical Field

[0003] The present invention relates to the field of radiopharmaceuticals, in particular to a compound targeting and binding to fibroblast activation protein and its application. Background Art

[0004] Fibroblast activation protein alpha (FAP-α, abbreviated as FAP) inhibitor (FAPI) for PET imaging is a strategy to target a cell population of the peritumoral stroma (cancer-associated fibroblasts). Although of different origin, cancer-associated fibroblasts can be identified by the upregulation of several surface markers, with FAP, a membrane-bound type II serine protease belonging to the dipeptidyl peptidase 4 family, being the most specific surface marker. Several approaches have been effectively used to target this molecule with radiolabeled ligands such as antibodies, peptides, or small molecule inhibitors. Among the FAP-based radiotracers currently under development, gallium-68[ 68 The high detection rate of FAPI labeled with Ga in various tumors provides favorable imaging evidence, even in tumors that are considered to be resistant to conventional [ 18 F] fluorodeoxyglucose ( 18 This is also true in cases where F-FDG PET is challenging. Fibroblast activation occurs not only in peritumoral tissue but also in benign situations such as wound healing, inflammation, or ischemia. Therefore, FAPIPET imaging may also have the potential to diagnose common benign diseases associated with a wide range of morbidity (Uwe Haberkor, Radiology, 2023, 306, 2).

[0005] FAP is a type II transmembrane glycoprotein composed of 760 amino acids. As a serine protease, unlike other members of the dipeptidyl peptidase (DPP) family, it has endopeptidase and exopeptidase activities, can cleave gelatin and type I collagen, and plays an important role in ECM remodeling. The amino acid sequence similarity between DPPIV and FAP is about 50%, and the homology of the catalytic domain is about 70%. FAP-expressing CAFs are present in many tumors, especially epithelial tumors, and malignant tumors with strong desmoplastic reactions, such as breast cancer, colorectal cancer, pancreatic cancer, and lung cancer. FAP has also been reported to be expressed in tumor cells of some tumors (Scanlan, MJ, Proc. Natl. Acad. Sci. USA 1994, 91, 5657–5661; Dohi, O Histopathology 2009, 55, 432–440). In general, high expression of FAP is associated with tumor aggressiveness and poor prognosis (Cohen, SJ, Pancreas 2008, 37, 154–158; Coto-Llerena, M, Front. Oncol. 2020, 10, 979). The expression of FAP in normal healthy adult tissues is negligible, making it a very attractive target for tumor imaging and treatment (Lindner, T, EJNMMI Radiopharm. Chem. 2019, 4, 16). FAP overexpression makes it a target for cancer diagnosis and treatment. Currently, there are mainly strategies such as antibodies, peptides, enzyme inhibitors, vaccines, immunoconjugates and chimeric antigen receptor T cells (Xin, L, Front. Oncol. 2021, 11, 3187). In 1994, Welt et al. first reported the use of 131I-labeled mouse monoclonal antibody (mAb) F19, clinical experience in FAP targeted imaging in patients with metastatic colorectal cancer (CRC) (Welt, S, J. Clin. Oncol. 1994, 12, 1193–1203). Subsequently, sibrotuzumab, a humanized antibody of mAb F-19, was developed to explore the possibility of FAP targeted therapy. However, a phase I clinical study reported that sibrotuzumab did not produce any objective tumor response in 26 patients with advanced colorectal or lung cancer expressing FAP, hindering the further development of related molecules (Scott, AM, Clin. Cancer Res. 2003, 9, 1639–1647). Radiolabeled antibodies are limited by their large molecular weight, resulting in slow clearance of tracers in the body, which leads to disadvantages such as high background signal, low sensitivity of lesion detection and high overall radiation exposure (Garousi, J, EJNMMI Radiopharm. Chem. 2020, 5, 16). Some early work on FAPI focused on pyrrolidine-2-boronic acid derivatives, such as talabostat mesylate (PT-100), an oral aminoboron dipeptide, but Talabostat has affinity for members of the DPP subfamily and is not very specific for FAP (Adams, S, Cancer Res. 2004, 64, 5471–5480). Eventually, the researchers shifted their focus to small molecule FAP inhibitors with N-(4-quinolyl)-gly-(2-cyanopyrrolidine) structures, which have good pharmacokinetics and higher FAP specificity. This structure was first developed by the University of Antwerp (Jansen, K, ACS Med. Chem. Lett. 2013, 4, 491–496; Jansen, K, J. Med. Chem. 2014, 57, 3053–3074). Subsequently, the Heidelberg team in Germany modified its structure and developed FAPI-01 and FAPI-02 as the first generation of quinoline-based FAPIs, and used 125 I and 68 Ga / 177 Lu was radiolabeled. 68 Compared with Ga]Ga-FAPI-02, 125I-labeled FAPI-01 has low binding and uptake to human FAPI-expressing cells in vitro and in vivo due to its time-dependent efflux and enzymatic deiodination (Loktev, A, J. Nucl. Med. 2018, 59, 1423–1429). Lindner et al. synthesized multiple FAPI derivatives (FAPI-03 to FAPI-15) based on a common pharmacodynamic functional group (UAMC1110). Among them, FAPI-04 has higher tumor uptake (3.0% vs 1.12% ID / g, 24h) and longer retention time than FAPI-02 (Lindner, T, J.Nucl. Med. 2018, 59, 1415–1422), and is considered to be the most promising tracer for treatment. Further attempts to improve intratumoral retention led to the discovery of FAPI-46 (Loktev, A, J. Nucl. Med. 2019, 60, 1421–1429). Most of the studies published on the clinical application of FAP targeting have used FAPI-04 and FAPI-46.

[0006] Many researchers around the world have used FAPI-04 and FAPI-46 to compare with F-FDG for diagnosis. Studies by Halil Kömek (Annals of Nuclear Medicine, 2021, 35:744–752) and Philipp Backhaus (Radiology 2022, 302:39–47) have confirmed that FAPI has better detection capabilities in breast cancer in situ and metastatic lesions. For pancreatic ductal carcinoma, several studies have also shown that FAPI has a higher detection rate (Li Huo, EJNMMI, 2023 50:4036–4050; Jens T. Siveke, J. Nucl. Med, 2023, 64, 1910-1917). In addition, FAPI has also been used in colorectal cancer (Ebubekir Gündeş, EJNMMI, 2022, 49, 3898–3909), cholangiocarcinoma (Wolfgang P. Fendler, JNucl Med, 2023, 64, 1049-1055) and other indications, all of which have shown good diagnostic capabilities. The excellent diagnostic capabilities of FAPI in various tumors make FAP targets a promising tool for future therapeutic applications, but FAPI-04 and FAPI-46 are cleared quickly in the body and do not match the half-life of therapeutic nuclides, which limits their clinical treatment.

[0007] Moon et al. developed a new FAPI radiotracer using a bifunctional chelator (DOTA, DATA5m, DOTAGA) and an aromatic acid (SA)-based linker between the UAMC1110 structure to simplify the previously complex synthesis of FAPI (Moon, ES, EJNMMI Radiopharm. Chem. 2020, 5, 19). 68 Ga-labeled DOTA.SA.FAPI has good imaging effect. However, using radionuclides 177 Lu-labeled drugs showed tracer shedding 48 hours after injection, limiting their clinical application. Subsequently, the same research group developed dimers, such as DOTA.(SA.FAPI)2 and DOTAGA.(SA.FAPI)2, to improve tumor affinity and retention time (Moon, ES, Am. J. Nucl. Med. Mol. Imaging 2021, 11, 476–491). 177 Lu, these dimers showed good therapeutic application results in early clinical studies (Ballal, S, Thyroid. 2021, 32, 65–77). Xu et al. coupled two albumin binders, 4-(p-iodophenyl)butyric acid fragments and truncated Evans blue fragments, to the parent molecule FAPI-04, respectively, to develop TEFAPI-06 and TEFAPI-07 (Xu, M, J. Nucl. Med. 2022, 63, 952–958). A research team in the United States has developed a trifunctional inhibitor RPS-309, which consists of a fragment targeting FAP, an albumin binding group, and DOTA for radioactive metal chelation. Onco-FAP is an ultra-high affinity FAP organic ligand that was successfully labeled with DOTAGA as a chelator. 68 Ga and 177 Lu. The development of these molecules helped improve rapid blood clearance and tumor retention time in vitro and in vivo (Kelly, JM, Mol. Imaging Biol. 2021, 23, 686–696; Millul, J, Proc. Natl. Acad. Sci. USA2021, 118).

[0008] Recently, a German research group developed a novel FAP-binding peptide, FAP-2286 (Zboralski, D, Eur. J. Nucl. Med. Mol. Imaging 2022, 49, 3651–3667), which is different from FAP small molecule inhibitors. FAP-2286 has been evaluated as a radiotracer at the preclinical and clinical levels.68 The tumor uptake ID% / g of Ga-FAP-2286 in mice at 1h and 3h reached 10.58% and 10.76%, respectively, which was higher than 10.05% and 9.23% of FAPI-46. 177 Lu-FAP-2286 uptake in the tumor reached 21.1% at 3h and 15.8% at 24h, which is much higher than 177 The 24h uptake of Lu-FAPI-46 (3.8%) showed excellent specific selection for FAP, high tumor uptake, high tumor retention, potential anti-tumor activity and acceptable toxicity (Baum, RP, J. Nucl. Med. 2022, 63, 415–423). Existing clinical trial data show that 68 The uptake of Ga-FAP-2286 in various tumors was significantly higher than 18 F-FDG, especially low to moderate uptake 18 F-FDG-positive cancer types, including gastric cancer (9.1 vs. 3.4), pancreatic cancer (13.0 vs. 6.5), and liver cancer (11.3 vs. 4.8) (HaojunChen, J Nucl Med, 2023, 64, 386-394); 177 The results of the first human trial of Lu-FAP-2286 showed that patients had significant changes in tumor lesions on SPECT imaging (72h-10d after injection). 177 The uptake and retention of Lu-FAP-2286 has a systemic effective half-life of 35; for bone metastases it is 44 h, showing relatively excellent therapeutic potential (Richard P. Baum, JNucl Med, 2022, 63, 415-423).

[0009] Another different molecular design can be based on the boric acid biologic N-(pyridine-4-carbonyl)-D-Ala-boroPro (3099), which was first discovered and characterized by Poplawski et al. The nanomolar potency and high selectivity of 3099 for FAP are superior to other DPP4-like subfamily enzymes, providing a basis for studying it as a FAP targeting fragment (Poplawski SE, J MedChem. 2013, 56: 3467–3477). William W. Bachovchin et al. used DOTA chelator to modify the structure of 3099 by connecting aminobenzoic acid residues (PNT6555) or tranexamic acid residues to D-alanine at the N-terminus (PNT6952) or Gly-Gly-Val tripeptide (PNT6522). The three molecules had a significant inhibitory effect on FAP sources in humans and mice. PNT6555 and PNT6952 were used68 Ga-labeled, it showed rapid renal clearance and sustained uptake in the tumor 60 min after administration, with intratumoral uptake (ID% / g) reaching 9% and 10.5% at 1 h, respectively; 177 Lu-PNT6555 has the highest uptake in animals within 24 hours, with ID% / g of approximately 24%, and then decreases. It has the greatest effect on delaying tumor growth, and 30MBq shows a tumor inhibitory effect, demonstrating its clinical application value (William W Bachovchin, J Nucl Med, 2024, 65, 100-108).

[0010] Although existing compounds are designed with high enzyme activity, they have low tumor retention and rapid metabolism, which is not conducive to radiotherapy.

[0011] In view of this, the present invention is proposed. Summary of the invention

[0012] The present invention provides a compound, specifically a targeted binding fibroblast activation protein (FAP) inhibitor or binder, a FAP-targeted nuclide probe drug based on the FAP binder, and use of the inhibitor and probe in the preparation of a tumor imaging agent and a tumor therapeutic agent targeting FAP.

[0013] In a first aspect, the present invention first provides a compound represented by formula (I) or a pharmaceutically acceptable tautomer, racemate, hydrate, solvate or salt thereof, wherein the structural formula of the compound represented by formula (I) is: (I); in, It is a nitrogen-containing 4-10 membered cyclic compound, wherein n is any integer from 0 to 6; R2, R3, and R4 are independently selected from -H, -F, -Cl, -Br, -I, -C 1-6 Alkyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, alkenyl, heteroalkenyl, cycloalkenyl, cycloheteroalkenyl, alkynyl, aryl or -C 1-6 Arylalkyl, the -C 1-6 Each of the alkyl groups is optionally substituted with 1 to 3 substituents selected from -OH, oxygen, and halogen; R5 is a 1-naphthyl moiety or a 5- to 10-membered N-containing aromatic or non-aromatic monocyclic or bicyclic heterocyclic ring, which optionally further contains 1, 2 or 3 heteroatoms selected from O, N and S; L represents a bond or a linker; R6 represents any of the following functional groups: an optical dye, a photodynamic therapy agent, a radioimaging agent, a radiotherapeutic agent, a chemotherapeutic agent, an anti-fibrotic agent or an anticancer agent.

[0014] Preferably, n is 1, that is It is a 5-membered cyclic compound containing nitrogen.

[0015] Preferably, the nitrogen-containing cyclic compound is a group of a fibroblast activation protein (FAP) ligand.

[0016] Preferably, R1 is selected from -H, -CN, -F, -F2, -B(OH)2, -C(O)-alkyl, -C(O)-aryl-, -C=CC(O)-aryl, -C=CS(O)2-aryl, -CO2H, -SO3H, -SO2NH2, -SO2F, -CH2SO2F, -PO3H2, cyclic ether or 5-tetrazolyl.

[0017] Preferably, Selected from .

[0018] Preferably, in the general formula (I), Select from any of the following structural formulas: ; Among them, R8, R9, R 10 There is no or independently 1 or 2 heteroatoms selected from O, N and S.

[0019] Preferably, Select from any of the following structural formulas: .

[0020] Preferably, Select from any of the following structural formulas: .

[0021] Preferably, L is an intermediate linking fragment between the active fragment and the metal complex.

[0022] Preferably, L comprises one or more linker groups, each linker group being independently selected from (alkylene), (heteroalkylene), (heterocycloalkylene), heteroaryl, aryl, alkoxy, thioether, disulfide, carboxylic acid, anhydride, carbonate, carbamate, thioether, sugar, peptide, polyethylene glycol (PEG), amide or ester.

[0023] Preferably, L independently or in any combination thereof comprises at least one linker group having the following structure: ; Wherein, n is any integer from 1 to 10.

[0024] More preferably, L comprises one or more of the following linker groups: ; wherein R7 is selected from -H, -C 1-6 Alkyl, -OC1-6 Alkyl, -SC 1-6 Alkyl, alkenyl, heteroalkenyl, cycloalkenyl, cycloheteroalkenyl, alkynyl, aryl or -C 1-6 Arylalkyl, the -C 1-6 Each of the alkyl groups is optionally substituted by 1 to 3 substituents selected from -OH, oxygen, and halogen; n is any integer from 1 to 10.

[0025] Preferably, R6 is a ligand moiety, which is a chelating agent that forms a complex with a divalent or trivalent metal cation; preferably, the chelating agent is selected from 1,4,7,10-tetraazacyclododecane-N,N',N,N'-tetraacetic acid (DOTA), ethylenediaminetetraacetic acid (EDTA), 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA), triethylenetetramine (TETA), iminodiacetic acid, diethylenetriamine-N,N,N',N',N"-pentaacetic acid (DTPA), bis-(carboxymethylimidazole)glycine or 6-hydrazinopyridine-3-carboxylic acid (HYNIC).

[0026] Alternatively, R6 is a ligand moiety, wherein the ligand moiety is a non-radioactive isotope, a radioactive isotope, a radiopharmaceutical or a combination thereof; preferably, the radioactive isotope is selected from an alpha-emitting isotope, a beta-emitting isotope, a gamma-emitting isotope, an Auger electron-emitting isotope, an X-ray-emitting isotope, for example 18 F. 18 F-Al, 51 Cr, 67 Ga, 68 Ga, 111 In, 99m Tc, 186 Re, 188 Re, 139 La, 140 La, 175 Yb, 153 Sm, 166 Ho, 88 Y. 90 Y. 149 Pm, 165 Dy, 169 2. 177 Lu, 47 Sc, 142 Pr, 159 Gd, 212 Bi, 213 Bi, 72 As, 72 Se, 97 Such as 109 Pd, 105 Rh, 101mRh, 119 Sb, 128 8. 123 I. 124 I. 131 I. 149 Tb, 152 Tb, 155 Tb, 161 Tb, 197 Hg, 211 At 151 Eu, 153 Eu, 169 Eu, 201 Tl, 203 Pb, 212 Pb, 64 Cu, 67 Cu, 188 Re, 186 Re, 198 Au, 225 Ac, 227 Th and 199 Ag et al. Alternatively, R6 is a ligand moiety selected from the following classes of fluorescent dyes: xanthines, acridines, oxazines, cyanines, styryl dyes, coumarins, porphyrins, metal ligand-complexes, fluorescent proteins, nanocrystals, perylene, boron dipyrromethene and phthalocyanines, and conjugates and combinations of these classes of dyes.

[0027] Alternatively, R6 is a contrast agent comprising or consisting of a paramagnetic agent; preferably, the paramagnetic agent comprises or consists of paramagnetic nanoparticles.

[0028] Preferably, the compound represented by formula (I) or its pharmaceutically acceptable tautomer, racemate, hydrate, solvate or salt has any of the following structural formulas: .

[0029] In a second aspect, the present invention provides a method for preparing the above-mentioned compound, and the reaction scheme thereof is as follows:

[0030] (a) A substituted pyrrole derivative A and a glycine derivative B undergo condensation reaction to form an amide C, which condenses with another amine D via an isocyanate intermediate in the presence of a carbonylating agent (such as triphosgene, BHT, etc.) under alkaline conditions to prepare compound E.

[0031] (b) The R5 formic acid derivative F with a connector at the end undergoes a Curtius rearrangement reaction in the presence of an azide (such as diphenylphosphoryl azide DPPA) and condenses with another amine C via an isocyanate intermediate to generate compound G, which then condenses with carboxylic acid H to prepare compound I.

[0032] In a third aspect, the present invention provides a pharmaceutical composition comprising the compound represented by formula (I) or a pharmaceutically acceptable tautomer, racemate, hydrate, solvate or salt thereof.

[0033] Preferably, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier and / or excipient.

[0034] In a fourth aspect, the present invention provides a targeted fibroblast activation protein (FAP) inhibitor or binder, which includes the compound represented by formula (I) or its pharmaceutically acceptable tautomer, racemate, hydrate, solvate or salt, or the pharmaceutical composition.

[0035] In a fifth aspect, the present invention provides a kit comprising the compound represented by formula (I) or its pharmaceutically acceptable tautomer, racemate, hydrate, solvate or salt or the pharmaceutical composition; and instructions for diagnosing or treating a disease.

[0036] In a sixth aspect, the present invention provides the use of the compound represented by formula (I) or its pharmaceutically acceptable tautomer, racemate, hydrate, solvate or salt or the pharmaceutical composition for preparing drugs for diagnosing and / or treating diseases.

[0037] Preferably, the disease comprises a disease characterized by overexpression of fibroblast activation protein (FAP) in an animal or human subject.

[0038] Further preferably, the disease is selected from cancer, chronic inflammation, atherosclerosis, fibrosis, tissue remodeling and scar disease.

[0039] More preferably, the cancer is selected from the group consisting of small intestine cancer, head and neck cancer, hepatocellular carcinoma, hypopharyngeal cancer, nasopharyngeal cancer, myeloma cells, cholangiocarcinoma, clear cell renal carcinoma, neuroendocrine tumors, carcinogenic osteomalacia, sarcoma, CUP (unknown primary cancer), thymic cancer, glioma, glioma, astrocytoma, cervical cancer, eye cancer, rectal cancer, colon cancer, cervical cancer, prostate cancer, breast cancer, bladder cancer, oral cancer, stomach cancer, liver cancer, pancreatic cancer, lung cancer, uterine cancer , ovarian cancer, testicular cancer, kidney cancer, brain cancer, central nervous system cancer, pharyngeal cancer, skin melanoma, acute lymphoblastic leukemia, acute myeloid leukemia, Ewing's sarcoma, Kaposi's sarcoma, basal cell carcinoma and squamous cell carcinoma, small cell lung cancer, choriocarcinoma, rhabdomyosarcoma, angiosarcoma, hemangioendothelioma, Wilms tumor, neuroblastoma, esophageal cancer, laryngeal cancer, lymphoma, neurofibroma, tuberous sclerosis, hemangioma or lymphoma.

[0040] In a seventh aspect, the present invention provides a tumor therapeutic agent, which contains the compound represented by formula (I) or its pharmaceutically acceptable tautomer, racemate, hydrate, solvate or salt or the pharmaceutical composition.

[0041] In an eighth aspect, the present invention provides a tumor imaging agent, which contains the compound represented by formula (I) or its pharmaceutically acceptable tautomer, racemate, hydrate, solvate or salt or the pharmaceutical composition.

[0042] In a ninth aspect, the present invention provides a tumor diagnostic agent, which contains the compound represented by formula (I) or its pharmaceutically acceptable tautomer, racemate, hydrate, solvate or salt or the pharmaceutical composition.

[0043] The compounds of the present invention introduce urea groups at specific positions in the structure. Although the enzyme activity is slightly reduced, the retention of the compounds at the target location (e.g., tumor site) can be effectively increased, and the clearance rate can be slowed down. The present invention can effectively improve tumor uptake, increase the retention time of the compounds at the tumor site, and realize the integrated diagnosis and treatment application of the compounds. In short, the present invention obtains compounds with longer retention time in tumors in vivo by modifying the structure of FAP-binding compounds. BRIEF DESCRIPTION OF THE DRAWINGS

[0044] In order to more clearly illustrate the technical solutions in the present invention or the prior art, the following briefly introduces the drawings required for use in the embodiments or the description of the prior art. Obviously, the drawings described below are some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0045] Figure 1For JYT2-212-1 in Example 1 of this application 1 H NMR.

[0046] Figure 2 This is the HPLC result of JYT2-212-1 in Example 1 of the present application.

[0047] Figure 3 This is the LC-MS result of JYT2-212-1 in Example 1 of the present application.

[0048] Figure 4 For JYT2-222-1 in Example 2 of this application 1 H NMR results.

[0049] Figure 5 This is the HPLC result of JYT2-222-1 in Example 2 of the present application.

[0050] Figure 6 This is the LC-MS result of JYT2-222-1 in Example 2 of the present application.

[0051] Figure 7 For JYT2-431-1 in Example 3 of this application 1 H NMR results.

[0052] Figure 8 This is the HPLC result of JYT2-431-1 in Example 3 of the present application.

[0053] Fig. 9 For JYT2-401 in Example 4 of this application 1 H NMR results.

[0054] Fig.10 This is the HPLC result of JYT2-401 in Example 4 of the present application.

[0055] Fig.11 This is the LC-MS result of JYT2-401 in Example 4 of the present application.

[0056] Fig.12 These are the test results of enzyme activities of different molecules.

[0057] Fig.13 for 68 HPLC quality control results after Ga-JYT2-401 labeling.

[0058] Fig.14 To inject different molecules 68 Ga-JYT2-401, 68 Ga-JYT2-411, 68 Ga-JYT2-441, 68Ga-JY2-011( 68 PET imaging results of HEK293 hFAP-bearing mice with Ga-PNT6555 tumors 1 hour later.

[0059] Fig.15 For injection 68 Ga-JYT2-401, 68 Ga-JYT2-411, 68 Ga-JYT2-441, 68 Ga-JY2-011( 68 Biodistribution results of HEK293 hFAP at different time points in Ga-PNT6555) tumor-bearing mice.

[0060] Fig.16 for 177 Lu-JYT2-401 quality control results.

[0061] Fig.17 For injection 177 Tissue distribution results of Lu-JYT2-401 injection in HEK293 hFAP human embryonic kidney cell Balb / c nude tumor-bearing mice.

[0062] Fig.18 In the middle, on the left is 177 SPECT images of Lu-JYT2-401 at different time points. The right side shows the changes in the maximum and average values ​​of tumor uptake in the SPECT image over time.

[0063] Fig.19 Middle, left side is for comparison 177 Lu-JYT2-401 and control group 177 Lu-FAP2286, 177 Lu-PNT6555( 177 The MIP image of SPECT imaging 48 hours after Lu-JY2-011 injection, and the right side is the comparison value of the maximum tumor uptake in the SPECT image.

[0064] Fig. 20 In contrast 177 Lu-JYT2-401 and control group 177 Tumor volume inhibition in HEK293 hFAP human embryonic kidney cell Balb / c nude mice (n=5) injected with 15 MBq of Lu-FAP2286 and saline group (vehicle).

[0065] Fig.21 In contrast 177 Lu-JYT2-401 and control group 177Survival curves of HEK293 hFAP human embryonic kidney cell Balb / c nude mice (n=5) injected with 15 MBq / mouse Lu-FAP2286 and saline groups (vehicle). DETAILED DESCRIPTION

[0066] In order to make the purpose, technical solution and advantages of the present invention clearer, the technical solution of the present invention will be clearly and completely described below in conjunction with the drawings of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0067] Example 1 Preparation of small molecule inhibitors

[0068] The synthetic route of JYT2-212-1 is as follows: .

[0069] Compound 3: S Preparation method of 4-(4-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-2-1-1-pyrrolidine-2-carbonitrile)-1-yl ... 石油醚 / 乙酸乙酯 = 2:1) to obtain intermediate 3 as a white solid (700 mg, 64%). LC-MS: [M+H] + = 312.7.

[0070] Compound 4: S Preparation method of 4-(4-difluoro-1-glycylpyrrolidine-2-carbonitrile: Add hydrochloric acid ethyl acetate solution (10 mL) to compound 3 (600 mg, 2.07 mmol) at 25°C. React at 25°C for 0.5 hours. Filter the reaction solution and concentrate under reduced pressure to obtain intermediate 4 (350 mg, 89%) as a white solid. LC-MS: [M+H] + = 190.1.

[0071] Compound JYT2-212-1: ( S )- NPreparation method of -(2-(2-cyano-4,4-difluoropyrrolidin-1-yl)-2-oxoethyl)-3,4-dihydroquinoline-1(2H)-carboxamide: o At 40 °C, BTC (93 mg, 0.31 mmol) and TEA (227 mg, 2.25 mmol) were added to a dichloromethane solution (5 mL) of intermediate 4 (85 mg, 0.45 mmol) and compound 5 (60 mg, 0.45 mmol). The mixture was stirred at 25 °C for 1 hour. The reaction solution was filtered and concentrated under reduced pressure to obtain a crude product. The crude product was purified by preparative HPLC (column: Gemini 5u C18 100 x 21.2 mm; mobile phase: ACN-H2O (0.1% FA); B%: 8%-15%, 10 min) to obtain JYT2-212-1 (10 mg, 6%) as a white solid.

[0072] JYT2-212-1 1 H NMR Figure 1 , HPLC results are shown in Figure 2 , LC-MS results are shown in Figure 3 .

[0073] LC-MS: [M+H] + = 349.1. 1 H NMR (400 MHz, DMSO- d 6 ) δ 7.52 (d, J = 8.0 Hz, 1H), 7.12-7.09 (m, 2H), 6.96-6.89 (m, 1H), 6.90 -6.88 (m, 1H), 5.08 -5.06 (m, 1H), 4.27 – 4.16 (m, 1H), 4.06 -3.92 (m, 1H), 3.92-3.90 (m, 2H), 3.64 – 3.58 (m, 2H), 2.95 – 2.76 (m, 2H), 2.70-2.68 (m, 2H), 1.89 – 1.79 (m, 2H).

[0074] Example 2 Preparation of small molecule inhibitors

[0075] JYT2-222-1 Synthesis route: .

[0076] Compound JYT2-222-1: ( S ) - NPreparation method of -(2-(2-cyano-4,4-difluoropyrrolidin-1-yl)-2-oxoethyl)-3,4-dihydroquinoline-1(2H)-carboxamide: o At 40 °C, BTC (55 mg, 0.19 mmol) and TEA (134 mg, 1.32 mmol) were added to a dichloromethane solution (5 mL) of intermediate 4 (50 mg, 0.26 mmol) and compound 5 (35 mg, 0.26 mmol). The mixture was stirred at 25 °C for 1 hour. The reaction solution was filtered and concentrated under reduced pressure to obtain a crude product. The crude product was purified by preparative HPLC (column: Gemini 5u C18 100 x 21.2 mm; mobile phase: ACN-H2O (0.1% FA); B%: 12%-19%, 10 min) to obtain JYT2-222-1 (7 mg, 7%) as a white solid.

[0077] JYT2-222-1 1 H NMR Figure 4 , HPLC results are shown in Figure 5 , LC-MS results are shown in Figure 6 .

[0078] LC-MS: [M+H] + = 350.1. 1 H NMR (400 MHz, DMSO- d 6 ) δ 7.26 – 7.22 (m, 1H), 6.88 – 6.82 (m, 1H), 6.61-6.54 (m, 2H), 6.53 – 6.48 (m, 1H), 6.11 (s, 1H), 5.07-5.05 (m, 1H), 4.24 – 4.13 (m, 1H), 4.09 – 3.96 (m, 1H), 3.91 d, J = 5.6 Hz, 2H), 3.60– 3.47 (m, 2H), 3.22 (d, J = 2.8 Hz, 2H), 2.82-2.76 (m, 2H).

[0079] Example 3 Preparation of small molecule inhibitors

[0080] JYT2-431-1 Synthesis Route: .

[0081] Step 1: 7-((tert-butyldimethylsilyl)oxy)quinoline: Dissolve 7-hydroxyquinoline (5.0 g, 34.4 mmol) in DMF (50 mL), add tert-butyldimethylsilyl chloride (6.2 g, 41.3 mmol) and imidazole (3.5 g, 51.6 mmol). After addition, react at room temperature for 70 minutes. TLC detection shows that the raw material reacts completely. The reaction solution is quenched with water (200 mL), extracted with ethyl acetate (100 mL), washed with water (50 mL), separated, dried over anhydrous sodium sulfate, concentrated, and the crude product is purified by silica gel column chromatography (PE / EA = 20 / 1) to obtain the colorless liquid title compound 019C-069-1 (8.9 g, yield: 99.7%).

[0082] Step 2: 7-((tert-butyldimethylsilyl)oxy)-1,2-dihydroquinoline: Dissolve compound 019C-069-1 (2.0 g, 7.7 mmol) in anhydrous tetrahydrofuran (30 mL), add diisobutylaluminum hydride (15.4 mL, 15.4 mmol) at room temperature, raise the reaction temperature to 25°C and stir for 2 hours. TLC shows that most of the raw materials have reacted. Pour the reaction solution into ice water to quench, extract with ethyl acetate (100 mL), wash with water (50 mL), dry, and concentrate to obtain the light yellow title compound 019C-069-2 (2.1 g, crude product), which is used directly in the next step. LC-MS: m / z = 262.2 [M+H]+.

[0083] Step 3: 7-((tert-butyldimethylsilyl)oxy)quinoline-1(2H)-carbonyl chloride: Dissolve compound 019C-062-2 (1.5 g, crude product) in dichloromethane (40 mL), add triethylamine (567 mg, 5.6 mmol), cool the reaction mixture to 0°C under nitrogen protection, quickly add triphosgene (550 mg, 1.86 mmol) to the reaction mixture, and stir the mixture at 0°C for 10 minutes; TLC shows that the reaction of the raw material is complete. Add dilute hydrochloric acid (100 mL) to the reaction mixture and quench it. Separate the liquid, dry the organic phase over anhydrous sodium sulfate, and concentrate to obtain the title compound 019C-069-3 (1.4 g, crude product) as a reddish brown solid, which is used directly in the next step.

[0084] Step 4: 7-((tert-butyldimethylsilyl)oxy)-N-(2-oxo-2-((R)-2-((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methylenebenzo[d][1,3,2]dioxaborol-2-yl)pyrrolidin-1-yl)ethyl)quinoline-1(2H)-carboxamide: Compound 019C-062-2 (654 mg, 1.91 mmol) was dissolved in dichloromethane (20 mL), triethylamine (386 mg, 3.82 mmol) and compound 019C-069-3 (1.4 g, crude) were added, and the reaction was stirred at room temperature overnight. After the reaction was completed, dilute hydrochloric acid (100 mL) was added to quench. The organic phase was separated, and dried over anhydrous sodium sulfate and concentrated. The crude product was purified by silica gel column chromatography to obtain the title compound 019C-069-4 as a red solid (0.39 g, yield: 34%).

[0085] Step 5: 7-Hydroxy-N-(2-oxo-2-((R)-2-((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborol-2-yl)pyrrolidin-1-yl)ethyl)quinoline-1(2H)-carboxamide: Compound 019C-069-4 (0.39 g, 0.67 mmol) was dissolved in tetrahydrofuran (10 mL), and TBAF (10 mL, 10 mmol) was added. After the addition was complete, the reaction was stirred at room temperature for 1 hour. The reaction solution was quenched with water (100 mL); extracted with ethyl acetate (50 mL), separated, and the organic phase was dried over anhydrous sodium sulfate and concentrated to obtain the title compound 019C-069-5 as a white solid (205 mg, yield: 64%).

[0086] Step 6: (R)-(1-((7-hydroxy-1,2-dihydroquinoline-1-carbonyl)glycylamino)pyrrolidin-2-yl)boronic acid: Compound 019C-069-5 (205 mg, 0.43 mmol) was dissolved in a mixed solution of methanol (3 mL) and n-hexane (3 mL), and phenylboronic acid (156 mg, 1.28 mmol) and dilute hydrochloric acid (3N, 2d) were added. After the addition, the mixture was reacted at room temperature overnight. TLC showed that the reaction of the raw material was complete. The liquid was separated, and the methanol layer was purified by preparative liquid chromatography (prep-HPLC) to obtain 58 mg of a white solid, which was further purified by preparative thin layer chromatography (Prep TLC) (DCM / MeOH = 10 / 1) to obtain the title compound SUS019C-069 (JYT2-431-1) as a white solid (25 mg, yield: 17%).

[0087] The synthesis results of JYT2-431-1 are as follows: 1 H NMR results are shown in Figure 7 HPLC results are shown in Figure 8 .

[0088] LC-MS: m / z = 328.2 [M-H2O+1] + (96.97% purity, 254 nm). 1 H NMR (400 MHz, CD3OD) δ 7.03-6.96 (m, 2H), 6.56 (dd, J = 8.0 Hz, 6.0Hz, 1H), 6.45 (d, J = 7.1Hz, 1H), 5.87-5.82 m, 1H), 4.32-4.22 (m, 2H), 4.07-3.96 (m, 2H), 3.63-3.46 (m, 2H), 3.13-3.00 (m, 1H), 2.21-2.12 (m, 1H), 2.07-1.92 (m, 2H), 1.71-1.58 (m, 1H).

[0089] Example 4 Preparation of small molecule inhibitors

[0090] JYT2-201-1 synthesis results: Referring to the above synthetic route, the synthetic results of JYT2-201-1 are as follows: 3-{2-[(2S)-2-cyano-4,4-difluoropyrrolidin-1-yl]-2-oxoethyl}-1-(6-methoxyquinolin-4-yl)urea (900 mg, 2.3 mmol) and BBr3 (1 Min DCM) (11.6 mL) were dissolved in DCM (10 mL, and the reaction was stirred at 25 °C for 16 h. LCMS showed that the raw materials were consumed and the desired product was detected. Pre-HPLC (preparation conditions: chromatographic column: WELCH xmax C18 21.2 x250mm 10um), mobile phase: ACN—H2O (0.1% FA) gradient: 10-30%) was used to obtain the product (200 mg, yield 23%) as a white solid.

[0091] LC-MS: [M+H] + : 376.1. 1H NMR (400 MHz, DMSO) δ 9.13 (s, 1H), 8.45 (d, J = 5.2 Hz, 1H), 8.33 (s, 2H), 8.06 (d, J = 5.2 Hz, 1H), 7.79 (d, J = 9.0 Hz, 1H), 7.51 (s, 1H), 7.38 – 7.29 (m, 2H), 5.13 (d, J = 9.2 Hz, 1H), 4.27 – 4.03 (m, 4H), 2.87 – 2.75 (m, 2H).

[0092] Example 5 Preparation of small molecule inhibitors

[0093] JYT2-243-1 synthesis results: Referring to the above synthetic route, compound JYT2-243-1: 1-(2-((1S, 3S, 5S)-3-cyano-2-azabicyclo[3.1.0]hex-2-yl)-2-acetyl)-3-(6-hydroxyquinolin-4-yl)urea was synthesized as follows. In a nitrogen environment, BBr3 (1 mol / L dichloromethane solution) (411.35 mg, 1.64 mmol) was added to a dichloromethane solution (10 mL) of 3-{2-[(1S, 3S, 5S)-3-cyano-2-azabicyclo[3.1.0]hex-2-yl]-2-acetyl}-1-(6-methoxyquinolin-4-yl)urea (120 mg, 0.33 mmol) at 0°C. The mixture was stirred at 0°C for 12 hours. The reaction was quenched with water (1 mL) and MeOH (1 mL). The crude product was purified by preparative HPLC (column: Phenomenex luna C18 250 mm x100 mm x 10 um; mobile phase: [H2O (0.1% NH4HCO3)-ACN]; B%: 15%-35%, 9 minutes) to obtain a yellow solid JYT2-243-1 (2.5 mg, 2.2%).

[0094] LC-MS: [M+H] + : 352.1. 1H NMR (400 MHz, DMSO-d6) δ 9.93 (s, 1H), 9.10 (s, 1H), 8.45 (d, J = 5.2 Hz, 1H), 8.08 (d, J = 5.2 Hz, 1H), 7.80 (d, J = 9.0Hz, 1H), 7.47 (d, J = 2.4 Hz, 1H), 7.31 (dd, J = 9.0, 2.5 Hz, 2H), 4.97 (dd, J = 131.4, 9.0 Hz, 1H), 4.36 (dt, J = 18.2, 9.0 Hz, 1H), 4.16 (dd, J = 17.8, 4.8 Hz, 1H), 3.73 (dd, J = 37.8, 30.0 Hz, 1H), 2.56 (d, J = 13.2 Hz, 1H), 2.28 – 2.15 (m, 1H), 1.99 – 1.82 (m, 1H), 1.08 – 0.97 (m, 1H), 0.82 – 0.71 (m, 1H).

[0095] Example 6 Preparation of small molecule inhibitors

[0096] JYT2-253-1 synthesis results: Referring to the above synthetic route, compound JY2-253-1: (S)-1-(2-(2-cyano-4,4-difluoropyrrolidin-1-yl)-2-oxoethyl)-3-(1H-pyrrolo[2,3-b]pyridin-4-yl)urea was synthesized as follows: 2-Chloropyridine (177 mg, 1.56 mmol) and Tf2O (220 mg, 0.779 mmol) were added to a DCM (4 mL) solution of compound 3 (150 mg, 0.519 mmol) at 25°C. The reaction solution was stirred at 25°C for 30 minutes, compound 4 (207 mg, 1.56 mmol) and TEA (315 mg, 3.11 mmol) were added to the reaction solution, and the reaction was carried out at 25°C for 2 hours. LCMS showed that the product had been formed. The mixture was vacuum filtered and concentrated under reduced pressure. The crude product was purified by preparative high performance liquid chromatography (column Welch 21.2 x 250mm10um C18, 30ml / min), mobile phase: ACN-H2O (0.1% NH3); B%: 30%-70%, 10 min) to obtain a white powdery solid compound JYT2-253-1 (19.1 mg, 11%).

[0097] LC-MS: (ESI) m / z [M+H] + : 349.2. 1 H NMR (400 MHz, DMSO-d6) δ 10.33 (t, J = 5.4 Hz, 1H), 7.87 (d, J = 5.6 Hz, 1H), 7.58 (d, J = 3.8 Hz, 1H), 6.77 (d, J = 4.0 Hz, 1H), 6.68 (s, 2H), 6.38 (d, J = 5.8 Hz, 1H), 5.13 (dd, J = 9.2, 2.6 Hz, 1H), 4.39 – 4.18 (m, 3H), 4.18 – 4.03 (m, 1H), 2.97 – 2.75 (m, 2H).

[0098] Example 7 Preparation of small molecule inhibitors

[0099] JYT2-242-1 synthesis results: Referring to the above synthetic route, compound JYT2-242-1: (S)-1-(2-(2-cyano-4,4-difluoropyrrolidin-1-yl)-2-oxoethyl)-3-(6-hydroxyquinolin-4-yl)-1-methylurea was synthesized as follows: BBr3 (177 mg, 0.71 mmol) was added to a dichloromethane solution (2 mL) of intermediate 8 (57 mg, 0.14 mmol) at 0 °C. Stir at 25 °C for 1 hour. The reaction solution was quenched with methanol, filtered, and concentrated under reduced pressure to obtain a crude product. The crude product was purified by preparative HPLC (column: Gemini 5u C18 100 x 21.2 mm; mobile phase: ACN-H2O (0.1% FA); B%: 7%-12%, 10 min) to obtain JYT2-242-1 (6 mg, 9%) as a white solid.

[0100] LC-MS: [M+H] + : 390.2. 1H NMR (400 MHz, DMSO-d6) δ 10.06 (s, 1H), 8.72 (s, 1H), 8.55 (d, J = 4.2 Hz, 1H), 7.85 (d, J = 8.8 Hz, 1H), 7.57 (d, J = 4.6Hz, 1H), 7.34 (d, J = 9.2 Hz, 2H), 5.13 (d, J = 8.4 Hz, 1H), 4.31 – 4.18 (m, 2H), 4.14 – 3.90 (m, 2H), 3.13 (s, 3H), 2.87-2.80 (m, 2H).

[0101] Example 8 Preparation of small molecule inhibitors

[0102] JYT2-231-1 synthesis results: Referring to the above synthetic route, the synthesis results of compound JY2-231-1: (S) -N-(2-(2-cyano-4,4-difluoropyrrolidin-1-yl)-2-oxoethyl)isoindoline-2-carboxamide are as follows: BTC (67 mg, 0.22 mmol) and TEA (91 mg, 0.89 mmol) were added to a dichloromethane solution (5 mL) of intermediate 4 (85 mg, 0.45 mmol) and compound 5 (54 mg, 0.45 mmol) at 25 °C. Stir at 25 °C for 1 hour. The reaction solution was filtered and concentrated under reduced pressure to obtain a crude product. The crude product was purified by preparative HPLC (column: Gemini 5u C18 100 x 21.2 mm; mobile phase: ACN-H2O (0.1% FA); B%: 10%-15%, 10 min) to obtain JY2-231-1 (20 mg, 13%) as a white solid.

[0103] LC-MS: [M+H] + : 335.1. 1 H NMR (400 MHz, DMSO-d6) δ 7.37 – 7.27 (m, 4H), 6.70-6.67 (m, 1H), 5.08-5.05 (m, 1H), 4.63 (s, 4H), 4.30 – 4.20 (m, 1H), 4.09-3.90 (m, 1H), 3.90-3.84 (m, 2H), 2.98 – 2.73 (m, 2H).

[0104] Example 9 Preparation of small molecule inhibitors

[0105] JYT2-441-1 synthesis results: The synthetic route is as follows: .

[0106] Step 1: 7-((tert-butyldimethylsilyl)oxy)naphthalene-1-amine: 8-amino-2-naphthol (3.2 g, 20.0 mmol) was dissolved in DMF (20 mL), and tert-butyldimethylsilyl chloride (3.6 g, 24.0 mmol) and imidazole (2.8 g, 41.0 mmol) were added. After addition, the reaction was carried out at room temperature for 30 minutes. TLC detected that the reaction of the raw material was complete. The reaction solution was quenched with water (100 mL), extracted with ethyl acetate (100 mL), washed with water (50 mL), separated, and the organic phase was dried over anhydrous sodium sulfate and concentrated. The crude product was purified by silica gel column chromatography (PE / EA = 20 / 1) to obtain the colorless liquid title compound 019C-068-1 (4.7 g, yield: 85.9%).

[0107] Step 2: tert-Butyl ((8-isocyanatonaphthalene-2-yl)oxy) dimethylsilane: Dissolve triphosgene (179 mg, 0.60 mmol) in dichloromethane (10 mL) and cool to -10°C under nitrogen protection. Dissolve compound 019C-068-1 (0.5 g, 1.83 mmol) in dichloromethane (15 mL) and add triethylamine (407 mg, 4.03 mmol). Slowly drop the obtained mixture into triphosgene, keeping the temperature below 0°C during the dropwise addition. After the dropwise addition is completed, the reaction is stirred at room temperature for 30 minutes to obtain a dichloromethane solution of compound 019C-068-2, which is directly used in the next step.

[0108] Step 3: 1-(7-((tert-butyldimethylsilyl)oxy)naphthalen-1-yl)-3-(2-oxo-2-((R)-2-((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methylenebenzo[d][1,3,2]dioxaborol-2-yl)pyrrolidin-1-yl)ethyl)urea: Compound 019C-062-2 (400 mg, 1.16 mmol) was added to the above reaction solution, and triethylamine (281 mg, 2.78 mmol) was added. The reaction was stirred at room temperature for 50 minutes. Dilute hydrochloric acid (100 mL) was added to quench the reaction. The organic phase was separated, dried over anhydrous sodium sulfate, concentrated, and the crude product was purified by silica gel column chromatography to obtain the title compound 019C-068-3 as a red solid (0.65 g, yield: 92.5%). LC-MS: m / z = 452.2 [MH] - .

[0109] Step 4: (R)-(1-(((7-hydroxynaphthalen-1-yl)carbamoyl)glycinylamino)pyrrolidin-2-yl)boronic acid: Compound 019C-068-3 (300 mg, 0.50 mmol) was dissolved in a mixed solution of methanol (4 mL) and n-hexane (4 mL), and phenylboronic acid (91 mg, 0.74 mmol) and dilute hydrochloric acid (3N, 2d) were added. The reaction solution was heated to 40°C for 5 hours. TLC showed that the reaction of the raw material was complete. The liquid was separated, the organic phase was concentrated, and the crude product was purified by Pre-TLC (DCM / MeOH = 10 / 1), and then slurried with methanol to obtain the yellow solid title compound SUS019C-068 (JYT2-441-1) (63 mg, yield: 35.59%).

[0110] Referring to the above synthetic route, compound JYT2-441-1: (R)-(1-(((7-hydroxynaphthalen-1-yl)carbamoyl)glycylamino)pyrrolidin-2-yl)boronic acid; the results are as follows: LC-MS: m / z = 340.2 [M-H2O-H] - (99.92% purity, 220 nm). 1 H NMR (400 MHz, DMSO-d6+D2O) δ 7.81-7.72 (m, 2H), 7.50 (d, J= 8.0 Hz, 1H), 7.36 (d, J= 2.0 Hz, 1H), 7.25-7.17 (m, 1H), 7.12 (dd, J =8.8, 2.4 Hz, 1H), 3.98-3.74 (m, 2H), 3.51-3.30 (m, 2H), 2.98-2.85 (m, 1H), 2.02-1.50 (m, 4H).

[0111] Example 10 Preparation of small molecule inhibitors

[0112] The synthetic route of JYT2-421-1 is as follows: .

[0113] Step 1: (S)-2-(R)-2-((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methylbenzo[d][1,3,2]dioxolan-2-yl)pyrrolidine-1-carbonyl)pyrrolidine-2-carboxylic acid tert-butyl ester: Compound 019C-062-2 (1.15 g, 4.65 mmol), N-Boc-L-proline (1.00 g, 4.65 mmol) and N,N,N′,N′-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate (2.65 g, 6.97 mmol) were dissolved in tetrahydrofuran (10 mL) and N,N-diisopropylethylamine (1.80 g, 13.94 mmol) was added. After the addition, the reaction was stirred at room temperature for 2 hours. TLC (ethyl acetate = 100%, potassium permanganate color development) monitoring showed obvious new spots. After adding water (20 mL) to quench the reaction, ethyl acetate was extracted (10 mL x2), the organic phases were combined, washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. The crude product was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 1) to obtain the title compound 019C-065-1 as a colorless transparent oil (1.07 g, yield: 52.1%).

[0114] Step 2: (R)-1-(L-propionyl)-2-((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methylbenzo[d][1,3,2]dioxol-2-yl)pyrrolidine hydrochloride: Disperse compound 019C-065-1 (1.07 g, 2.40 mmol) in hydrogen chloride / 1,4-dioxane (10 mL, 4N) and stir at 25°C for 2 hours. The reaction was completed by monitoring the reaction of the raw material by TLC (ethyl acetate = 100%). The reaction solution was concentrated to obtain the title compound 019C-065-2 (crude product) as a white solid, which was directly used in the next step.

[0115] Step 3: (S)-N-(6-Hydroxyquinolin-4-yl)-2-(R)-2-(((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methylbenzo[d][1,3,2]dioxolan-2-yl)pyrrolidine-1-carbonyl)pyrrolidine-2-carboxamide: Disperse compound 019C-062-5 (106 mg, 0.39 mmol), diisopropylethylamine (169 mg, 1.31 mmol) and diphenylphosphoryl azide (129 mg, 0.47 mmol) in toluene (6 mL), warm to 80 °C and stir for 2 hours. Monitor the disappearance of the starting material by TLC (dichloromethane / methanol = 9 / 1). Add compound 019C-065-2 (100 mg, crude product). The reaction was stirred at 80°C for 16 hours, and new spots were generated by TLC (dichloromethane / methanol = 9 / 1). The reaction solution was concentrated and purified by silica gel column chromatography (dichloromethane / methanol = 19 / 1) to obtain the light yellow oily title compound 019C-065-3 (95 mg, yield: 68.3%). LC-MS: m / z = 531.2 [MH]-.

[0116] Step 4: ((R)-1-(((6-Hydroxyquinolin-4-yl)carbamoyl)-L-propionyl)pyrrolidin-2-yl)boronic acid: Compound 019C-065-3 (95 mg, 0.18 mmol) and phenylboronic acid (44 mg, 0.36 mmol) were dissolved in a mixed solution of methanol (3 mL) and n-hexane (3 mL). Dilute hydrochloric acid (0.1 mL, 3N) was added dropwise. The reaction was stirred at 25°C for 3 hours, and TLC (dichloromethane / methanol = 9 / 1) monitored the complete reaction of the raw material. The lower methanol phase was aspirated with a pipette. After concentration, prep-TLC purification and pre-HPLC were used to prepare the off-white solid title compound SUS019C-065 (JYT2-421-1) (12 mg, yield: 16.9%).

[0117] Referring to the above synthetic route, compound JYT2-421-1: ((R)-1-(((6-hydroxyquinolin-4-yl)carbamoyl)-L-propionyl)pyrrolidin-2-yl)boronic acid; the results are as follows: LC-MS: m / z = 399.2 [M+H] + (98.98% purity, 220 nm). 1H NMR (400 MHz, D2O) δ 8.54-8.47 (m, 1H), 8.02-7.95 (m, 1H), 7.93-7.86 (m, 1H), 7.61-7.54 (m, 1H), 7.51-7.41 (m, 1H), 3.86-3.65 (m, 3H), 3.49-3.33 (m, 2H), 3.01-2.88 (m, 1H), 2.42-2.23 (m, 1H), 2.15-1.80 (m, 6H), 1.66-1.52 (m, 1H).

[0118] JYT2-453-1 synthesis results: Referring to the above synthesis route, compound JYT2-453-1: (R)-(1-(((1,7-naphthyridin-4-yl)carbamoyl)glycol)pyrrolidin-2-yl)boronic acid; the results are as follows: LC-MS: m / z = 344.1 [M+H] + (98.12% purity, 220 nm). 1 H NMR (400 MHz, DMSO-d6) δ 9.52 (s, 1H), 8.99 (d, J = 6.4 Hz, 1H), 8.94-8.88 (m, 2H), 8.49 (d, J = 6.0 Hz, 1H), 4.25-4.11 (m, 2H), 3.66-3.59 (m, 1H), 3.55-3.46 (m, 1H), 3.16-3.12 (m, 1H), 2.23-2.12 (m, 1H), 2.08-1.97 (m, 2H), 1.81-1.66 (m, 1H).

[0119] Example 11 Preparation of complete small molecule inhibitors

[0120] The synthetic route of JYT2-401 is as follows: .

[0121] Step 1: Preparation of 6-hydroxyquinoline-4-carboxylic acid methyl ester: Disperse 6-hydroxyquinoline-4-carboxylic acid hydrobromide (5.0 g, 18.51 mmol) in methanol (50 mL) and add concentrated sulfuric acid (0.5 mL). React at 65°C for 15 hours. TLC detection shows that the raw material has reacted completely. Concentrate the reaction solution to remove methanol, dilute with water (20 mL), add saturated sodium bicarbonate solution to alkalize to pH = 10, and add ethyl acetate (200 mL) for extraction. Filter and separate. Add ethyl acetate (50 mL x3) to the aqueous phase for extraction, combine the organic phases, and concentrate to obtain the title compound 401-1 as a brown solid (1.5 g, yield: 39.89%).

[0122] Step 2: Preparation of methyl 6-(3-(4-(tert-butoxycarbonyl)piperazine-1-yl)propoxy)quinoline-4-carboxylate: Compound 401-1 (1.3 g, 6.40 mmol) was dissolved in DMF (15 mL), and potassium carbonate (2.65 g, 19.2 mmol) and tert-butyl 4-(3-bromopropyl)piperazine-1-carboxylate (1.97 g, 6.40 mmol) were added. After the addition, the reaction solution was heated to 85°C for 2 hours. TLC detected that the raw material had reacted completely. The reaction solution was quenched with water (50 mL), extracted with ethyl acetate (100 mL x2), the organic phases were combined, concentrated, and the crude product was purified by silica gel column chromatography (PE / EA = 1 / 2) to obtain the brown liquid title compound 401-2 (1.75 g, yield: 63.64%). LC-MS: m / z = 430.2 [M+H] + .

[0123] Step 3: Preparation of 6-(3-(4-(tert-butoxycarbonyl)piperazine-1-yl)propoxy)quinoline-4-carboxylic acid: Disperse compound 401-2 (1.75 g, 4.09 mmol) in a mixed solution of THF (20 mL) and water (10 mL), and add LiOH.H2O (503 mg, 12.3 mmol). After the addition, the reaction solution was reacted at room temperature for 3 hours. TLC detected that the raw material had reacted completely. Saturated ammonium chloride was added to the reaction solution to acidify to pH = 6, and 2-methyltetrahydrofuran (50 mL x3) was added for extraction. The organic phases were combined and concentrated to obtain the white liquid title compound 401-3 (1.64 g, yield: 97.04%). LC-MS: m / z = 416.2 [M+H] + .

[0124] Step 4: Preparation of tert-butyl 4-(3-((4-(2-oxo-2-((R)-2-((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methylbenzo[d][1,3,2]dioxolan-2-yl)pyrrolidin-1-yl)ethyl)ureido)quinolin-6-yl)oxy)propyl)piperazine-1-carboxylate: Compound 401-3 (905 mg, 2.18 mmol) and compound 066-2 (746 mg, 2.18 mmol) were dispersed in toluene (15 mL), and triethylamine (661 mg, 6.54 mmol) and DPPA (660 mg, 2.4 mmol) were added. After the addition, the reaction solution was heated to 110°C for 3 hours. TLC detected that the reaction of the raw materials was complete. The reaction solution was quenched with water (50 mL), extracted with ethyl acetate (100 mL x2), the organic phases were combined and concentrated, and the crude product was purified by silica gel column chromatography (DCM / MeOH = 15 / 1) to obtain the yellow solid title compound 401-4 (491 mg, yield: 31.27%). LC-MS: m / z =719.4 [M+H] + .

[0125] Step 5: Preparation of 1-(2-oxo-2-((R)-2-(((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methylbenzo[d][1,3,2]dioxol-2-yl)pyrrolidin-1-yl)ethyl)-3-(6-(3-(piperazin-1-yl)propoxy)quinolin-4-yl)urea hydrochloride: Compound 401-4 (491 mg, 0.68 mmol) was dissolved in dichloromethane (2 mL), and 4M hydrochloric acid-dioxane solution (2 mL) was added. After the addition was completed, the reaction solution was reacted at room temperature for 2 hours. TLC detection showed that the reaction of the raw material was complete. The reaction solution was concentrated to obtain the title compound 401-5 as a yellow solid (430 mg, yield: 96.28%).

[0126] Step 6: Preparation of tri-tert-butyl 2,2',2'-(10-(2-oxo-2-(4-(4-(3-(2-oxy-2-((R)-2-((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methylbenzo[d][1,3,2]dioxolan-2-yl)pyrrolidin-1-yl)ethyl)ureido)quinolin-6-yl)oxy)propyl)piperazin-1-yl)ethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate: Dissolve tri-tert-butyl 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (39 mg, 0.069 mmol) in DMF (8 mL), add PYBOP (43 mg, 0.083 mmol) and DIPEA (27 mg, 0.21 mmol). After the addition, the reaction solution was stirred at room temperature for 30 minutes, and compound 401-5 (45 mg, 0.069 mmol) was added. After the addition, the reaction solution was reacted at room temperature for 3 hours. TLC detected that the raw material reaction was complete. The reaction solution was quenched with water (20 mL), extracted with ethyl acetate (20 mL x2), the organic phases were combined and concentrated, and the crude product was purified by Pre-TLC (DCM / MeOH = 10 / 1) to obtain the yellow solid title compound 401-6 (21 mg, yield: 26.05%). LC-MS: m / z = 587.5 [M+2H / 2] + .

[0127] Step 7: Preparation of 2,2',2'-(10-(2-oxo-2-(4-(4-(3-(2-oxy-2-((R)-2-((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methylbenzo[d][1,3,2]dioxolan-2-yl)pyrrolidin-1-yl)ethyl)ureido)quinolin-6-yl)oxy)propyl)piperazin-1-yl)ethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid: Compound 401-6 (21 mg, 0.018 mmol) was dissolved in dichloromethane (1 mL) and trifluoroacetic acid (2 mL) was added. The reaction was allowed to react at room temperature for 15 hours. The reaction solution was directly concentrated to obtain a purple solid 401-7 (crude product), which was directly used in the next step.

[0128] Step 8: Preparation of (R)-2,2',2'-(10-(2-(4-(3-(3-(2-(2-bromopyrrolidin-1-yl)-2-oxoethyl)ureido)quinolin-6-yl)oxy)propyl)piperazin-1-yl)2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid: Compound 401-1 (crude product) was dissolved in a mixed solution of water (2 mL) and acetonitrile (1 mL), and phenylboronic acid (2 mg, 0.016 mmol), trifluoroacetic acid (2d) and MTBE (6 mL) were added. After the addition, the reaction solution was reacted at room temperature for 3 hours. The liquid was separated, and MTBE (10 mL) was added to the aqueous phase for washing. The aqueous phase was subjected to Pre-HPLC to obtain the title compound JYT2-401 (10 mg, two-step yield: 38.77%) as a white solid.

[0129] JYT2-401 1 H NMR Fig. 9 , HPLC results are shown in Fig.10 , LC-MS results are shown in Fig.11 .

[0130] LC-MS: m / z = 853.4 [M-H2O+H] + (96.74% purity, 210 nm). 1 H NMR (400 MHz, D2O) δ 8.54 (d, J = 6.8 Hz, 1H), 8.39 (d, J = 6.8 Hz, 1H), 7.94 (d, J = 9.2 Hz, 1H), 7.69 (d, J = 2.0 Hz, 1H), 7.64 (dd, J = 9.2, 2.4 Hz, 1H), 4.62-4.44 (m, 1H), 4.31 (t, J = 5.2 Hz, 2H), 4.20-4.05 (m, 2H), 4.04-2.97 (m, 36H), 2.42-2.27 (m, 2H), 2.15-1.88 (m, 3H), 1.79-1.53 ​​(m, 1H).

[0131] Example 12 Preparation of complete small molecule inhibitors

[0132] Refer to the above synthetic route compound JYT2-402: 2,2',2'-(10-(4-(2-(4-(3-(2-(((R)-2-bromopyrrolidin-1-yl)-2-oxoethyl)ureido)quinolin-8-yl)amino)-4-oxobutyramido)ethyl)amino)-1-carboxy-4-oxobutyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid; the results are as follows: LC-MS: m / z = 470.7 [(M-H2O) / 2+H] + (97.43% purity, 210 nm); 1 H NMR (400 MHz, D2O) δ 8.58 (d, J = 6.8 Hz, 1H), 8.39 (d, J = 6.8 Hz, 1H), 8.28 (d, J = 8.4 Hz, 1H), 7.80 (d, J = 7.2 Hz, 1H), 7.76-7.71 (m, 1H), 4.04 (s, 2H), 3.70-3.68 (m, 5H), 3.53-3.44 (m, 4H), 3.39-3.32 (m, 2H), 3.28-3.13 (m, 10H), 2.99-2.88 (m, 6H), 2.76 (t, J = 6.4 Hz, 3H), 2.57 (t, J = 6.8 Hz, 2H), 2.23-1.54 (m, 10H).

[0133] Example 13 Preparation of complete small molecule inhibitors

[0134] Refer to the above synthetic route compound JYT2-406: (R)-2,2',2'-(10-(2-(4-(3-(3-(2-(2-bromopyrrolidin-1-yl)-2-oxoethyl)ureido)quinolin-6-yl)(methyl)amino)propyl)piperazin-1-yl)2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid; the results are as follows: LC-MS: m / z = 852.4 [M-H2O+H] + (98.44% purity, 210 nm); 1H NMR (400 MHz, D2O) δ 8.31 (dd, J = 18.4, 6.8 Hz, 2H), 7.80 (d, J = 9.2 Hz, 1H), 7.61 (dd, J = 9.6, 2.0 Hz, 1H), 6.96 (s, 1H), 4.65-4.44 (m, 1H), 4.40-4.08 (m, 2H), 4.12-2.99 (m, 41H), 2.35-1.90 (m, 5H), 1.91-1.53 ​​(m, 1H).

[0135] Example 14 Preparation of complete small molecule inhibitors

[0136] Refer to the above synthetic route compound JYT2-411: 2,2',2'-(10-(2-(4-(3-((R)-1-(R)-2-bromopyrrolidin-1-yl)-1-oxopropyl-2-yl)ureido)quinolin-6-yl)oxy)propyl)piperazin-1-yl)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid; the results are as follows: LC-MS: m / z = 434.3 [(M-H2O) / 2+H] + (96.81% purity, 210nm); 1 H NMR (400 MHz, D2O) δ 8.64 (d, J = 6.8 Hz, 1H), 8.46 (d, J = 6.8 Hz, 1H), 8.04 (d, J = 10.0 Hz, 1H), 7.81-7.70 (m, 2H), 4.76-4.69 (m, 1H), 4.69-4.53 (m, 1H), 4.48-4.29 (m, 2H), 4.15-3.69 (m, 13H) , 3.63-2.97 (m, 23H), 2.59-2.30 (m, 2H), 2.30-1.99 (m, 3H), 1.89-1.65 (m, 1H), 1.47 (d, J=6.8Hz, 3H).

[0137] Example 15 Preparation of complete small molecule inhibitors

[0138] Refer to the above synthetic route compound JYT2-441: 2,2',2'-(10-(2-oxy-2-(4-(3-(8-(3-(2-oxy-2-((R)-2-((3aS,4S,6S,7aR))-3a,5,5-trimethylhexahydro-4,6-methylbenzo[d][1,3,2]dioxol-2-yl)pyrrolidin-1-yl)ethyl)ureido)naphthalen-2-yl)oxy)propyl)piperazin-1-yl)ethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid; the result is as follows: LC-MS: m / z = 852.4 [M-H2O+H] + (98.79% purity, 220 nm); 1H NMR (400MHz, D2O) δ 7.81 (d, J = 9.2 Hz, 1H), 7.73 (d, J = 8.0 Hz, 1H), 7.43-7.28 (m, 2H), 7.24 (s, 1H), 7.13 (d, J = 8.8 Hz, 1H), 4.55-4.37 (m, 1H), 4.27-4.09 (m, 2H), 4.01-2.76 (m, 38H), 2.27-2.05 (m, 2H), 2.05-1.90 (m, 2H), 1.89-1.77 (m, 1H), 1.65-1.41 (m, 1H).

[0139] The structural formulas of FAPI04, JY2-011 (PNT6555), and FAP2286 reported in the literature are shown in Table 1.

[0140] Table 1

[0141] Experimental Example 1 Inhibitor affinity test

[0142] 1. Refer to the literature (Bioorg. Med. Chem. Lett. 2020, 30, 127253.). The specific operation is as follows: dilute the FAP protein concentration to 0.4μg / mL with assay buffer (25mM Tris, 250mM NaCl, pH 7.4); dilute the substrate GP-AMC to 40μM with assay buffer; prepare different concentrations of inhibitor (compound 1-20) solutions with assay buffer; add 25μL inhibitor and 25μL substrate to a 96-well black board in sequence, then add 50μL protein, place it in an ELISA reader, incubate at 37℃ for 1h, and measure its fluorescence intensity (Ex / Em=380 / 460nm); use Graphpad Prism fitting and sigmoidal 11dose response model to calculate IC50.

[0143] 2. Determination of the inhibitory activity of compounds on hFAP: The hFAP protein was diluted to 0.3 μg / mL using assay buffer (25 mM Tris, 250 mM NaCl, pH = 7.4) and kept on ice. The compound was diluted to a certain concentration gradient with assay buffer, namely 40 μM, 4 μM, 400 nM, 40 nM, 4 nM, 400 pM, 40 pM and 4 pM. The enzyme substrate Z-Gly-Pro-AMC was diluted to 40 μM with assay buffer and stored in the dark. The above-prepared 50 μL protein solution and 25 μL inhibitor were added to a 96-well plate (Corning 96-well ELISA plate with black transparent bottom, No. 3904) in sequence, centrifuged and shaken at room temperature for 30 min. Then, 25 μL of the above-prepared enzyme substrate was added. After incubation at room temperature for 3-5 hours, the fluorescence values ​​at an excitation wavelength of 360 nm and an emission wavelength of 465 nm were monitored using a multi-function microplate reader (Agilent BioTek Synergy H1). IC was calculated. 50 The value is defined as the concentration of the compound that causes a 50% decrease in enzyme activity under the assay conditions. The results are shown in Tables 2 and Fig.12 .

[0144] Table 2

[0145] 3. Location of other urea groups: The molecules JYT2-311-1, JTZ2-281-1 and JYZ2-291-1 with urea groups at different positions were synthesized. The synthetic routes were basically similar to those mentioned above, but the enzyme activity IC50 was much lower, all greater than 100uM.

[0146] The structural formulas and results of the molecules JYT2-311-1, JTZ2-281-1 and JYZ2-291-1 are shown below: .

[0147] Experimental Example 2 Labeling and Quality Control

[0148] 1. Preparation of test samples: Accurately measure 100 μL of 2M acetic acid-sodium acetate solution (pH 5.0) and place it in a 1.5ml centrifuge tube. Accurately add 2 μL of 20 nmol of the test sample (JTY2-401, JTY2-402, JTY2-406, JTY2-411, JTY2-441, JY2-011 (PNT6555), FAPI04, FAP2286) (10 nmol / μL) precursor aqueous solution, mix thoroughly, and add 0.3mL 68 GaCl3 eluent (activity: ~2.28 mCi) was heated vertically in a metal bath at 95 °C for 15 min under sealed conditions and then taken out. After the reaction was completed, 100 μL of 0.1% DTPA (pH 5.5) was added. After cooling to room temperature, a small amount of the post-reaction solution was taken for radiochemical purity analysis.

[0149] HPLC detection: JYT2-401 was tested by HPLC. The test conditions are shown in Table 3. The results are shown in Fig.13 .

[0150] Table 3

[0151] 2. 68 Imaging and biodistribution of Ga-labeled products

[0152] 2.1 PET / CT imaging

[0153] Towards 68 To the four Ga-labeled molecules (JYT2-401, JYT2-402, JYT2-411, JY2-011 (PNT6555), volume 350 μL) were added 500 μL PBS buffer and 32 μL 1M NaOH solution to prepare the test sample (pH ~ 6.1) (radioactivity concentration was about 2.7 μCi / μL). After mixing evenly, 75 μL was aspirated with an insulin syringe and the activity was measured. The results were JYT2-401: 192 μCi, JYT2-402: 193 μCi, JYT2-411: 199 μCi, JY2-011 (PNT6555): 203 μCi. They were injected into mice through the tail vein and the radioactivity in the mice was measured with an activity meter. Only ~120 μCi (~1 nmol) of molecules were injected into each mouse.

[0154] About 1 hour after administration, 180 μL of 1% sodium pentobarbital solution was drawn up by a syringe and intraperitoneally administered into the mouse to anesthetize the mouse. The anesthetized mouse was fixed to the PET / CT instrument bed, and the PET / CT was scanned after CT positioning.

[0155] After the scan is completed, the data is reconstructed and the ROI value is circled on the mouse PET data using software to obtain the radioactivity distribution %ID / g of organs and tissues such as the heart, kidneys, liver, muscles, bladder, and tumors.

[0156] Results Fig.14 The PET / CT 1h imaging results were analyzed by circumscribing the radioactive signals (%ID / g) in mouse organs and tumors. The results showed that JYT2-401 was comparable to the positive control JY2-011 (PNT6555).

[0157] 2.2 Biodistribution

[0158] injection 68 After Ga-labeling of different molecules FAPI04, FAP2286, JY2-011 (PNT6555), JTY2-401, JTY2-406, JTY2-411, and JTY2-441 tumor-bearing mice HEK293 hFAP n=3, the mice were dissected at different time points, and blood, heart, liver, spleen, lung, kidney, stomach, pancreas, small intestine, large intestine, muscle, femur, tumor, brain, and skin were collected. The collected organs and tissues were weighed, and the radioactivity in the organs and tissues was measured using a gamma counter.

[0159] The biodistribution results at different times are shown in Fig.15 Tail vein injection 68 Ga-labeled injections of different molecules FAPI04, FAP2286, JY2-011 (PNT6555), JTY2-401, JTY2-406, JTY2-411, and JTY2-441. Two hours after administration, radioactivity was enriched in different degrees in tissues and organs. 68 Ga-JTY2-401 and 68 Ga-FAPI04, 68 Ga-PNT6555, 68 The uptake of Ga-FAP2286 in tumors was comparable with no significant difference; its enrichment in other tissues and organs was low.

[0160] 3. 177 Lu labeling and quality control

[0161] 3.1 Marking process

[0162] Accurately measure 4 μL 20 nmol of compound (JYT2-401, FAP2286, JY2-011 (PNT6555)) solution, accurately add 50 μL pH 4.5 0.5 M sodium acetate buffer solution, shake thoroughly, and then add ~2 mCi (~2 μL) 177 The LuCl3 injection solution was mixed and heated at 95 °C in a sealed metal bath for 15 min. Then it was taken out and cooled to room temperature. 150 μL of 0.1% DTPA in PBS buffer solution was added. The radioactivity concentration of the solution was tested and a small amount was taken for radiochemical purity analysis. The radioactivity activity was tested before and after administration. The test sample was stored at room temperature and in a lead can and used immediately after preparation.

[0163] 3.2 Quality Control Analysis

[0164] Radiochemical purity: HPLC: Waters Xbridege 5 μm C-18 (4.6 × 150 mm), flow rate 1 mL / min; column temperature 35 °C; detection wavelength 210 nm; injection volume 20 μL (50-100 μCi). Gradient elution conditions are shown in Table 4.

[0165] Table 4

[0166] Results Fig.16 The radiochemical purity was calculated by the area normalization method and the radiochemical purity was greater than 95%, which met the test requirements.

[0167] The radiochemical purity was calculated by area normalization method and the radiochemical purity was greater than 95%, meeting the test requirements.

[0168] 3.3 177 Lu-JYT2-401 biodistribution

[0169] Animal identification: Each cage of animals must be hung with a cage card indicating the animal group, animal number, etc.

[0170] Feed provided: Mouse growth maintenance feed complies with GB14924.4-2001.

[0171] Feeding method: free feeding.

[0172] Drinking water: The drinking water bottles are supplied with high-pressure sterilized tap water. The tap water is inspected by the Taiyuan Monitoring Station of the National Urban Water Supply Quality Monitoring Network and meets the requirements of the "Sanitary Standards for Drinking Water" (GB5749-2006). The drinking water bottles are replaced every 2 days and are cleaned and sterilized under high pressure before use.

[0173] Tumor inoculation: The animal model was constructed by Beijing Weitonglihua Animal Technology Co., Ltd. HEK293 tumor cells were subcutaneously inoculated on the right side of the back of each experimental animal. A total of 10 animals were used for later experiments.

[0174] The experiment was divided into 3 groups. The mice were weighed before grouping and randomly divided into groups according to the animal weight and tumor size.

[0175] The grouping information is shown in Table 5.

[0176] Table 5

[0177] The drug solution was drawn with a disposable syringe, and the activity (μCi) was detected by an activity meter before administration (full needle). The drug was injected into the tail vein, and the residual radioactivity count (μCi) was detected by an activity meter after administration (empty needle). 177 The dosage of Lu-JYT2-401 injection is shown in Table 6.

[0178] Table 6 177 Lu-JYT2-401 Injection Dosage Table

[0179] Sampling time: 2 h, 24 h, and 48 h after administration.

[0180] Tissues and organs: The animals were lightly anesthetized, their eyeballs were removed and blood was drawn (blood samples were retained), and the heart, liver, spleen, lungs, kidneys, stomach (contents removed), large intestine (contents removed), small intestine (contents removed), femur (hind limbs), kneecap, muscle, pancreas, brain, bladder (no urine), tumor, skin, urine, feces (2-3 grains in the large intestine), administration site (tail) and the rest of the carcass were removed.

[0181] γ counter detection: biological samples are collected at various time points, gently squeezed and residual blood is absorbed with absorbent paper, weighed and recorded, and placed in EP tubes for γ counter detection. Samples are loaded for detection within 24 hours (if the radioactive count is too high, it can be measured after decay). The test results are expressed in CPM (CPM: radioactive counts per minute).

[0182] Data processing and analysis: %ID / g=A tissue / [(A0-A residue )*M tissue ]×100%.

[0183] A0: Total radioactivity count in the syringe before administration (CPM).

[0184] A residue : Residual radioactivity count in the syringe after administration (CPM).

[0185] A tissue : Radioactivity counts in tissues and organs (CPM).

[0186] M tissue : Weight of tested tissue sample (g).

[0187] Physical attenuation correction: 177 Lu physical decay: activity dose at time T = 0.5^(T / 160.8).

[0188] Dosage (A0-A residue ) multiplied by the decay coefficient of the corresponding time is the corrected CPM value and %ID / g is calculated.

[0189] Note: Within the activity range of no more than 75 μCi, the calibration curve of the activity meter detection (μCi) and the γ counter (CPM) is Y=135628X(R 2 =0.9991).

[0190] The results are shown in Table 7 and Fig.17 HEK293 human embryonic kidney cell Balb / c nude tumor-bearing mice were injected with a single tail vein injection 177 Lu-JYT2-401 injection, with the extension of time, the radioactive uptake in the blood decreased significantly; within the range of 2h to 48h after administration, there were different degrees of radioactive enrichment in tissues and organs, with the highest distribution in tumor, kidney and liver (%ID / g at each time point: tumor 34.70 ± 10.56, 18.37 ± 7.97 and 13.64 ± 1.85; kidney 4.16 ± 1.49, 2.26 ± 0.24 and 1.16 ± 0.36, liver 2.03 ± 0.76, 1.57 ± 0.10 and 1.02 ± 0.19); followed by skin, intestines, lungs, bladder, spleen, etc., and the lowest distribution in the brain.

[0191] Table 7 177 Results of tissue distribution of Lu-JYT2-401 injection in HEK293 human embryonic kidney cell Balb / c nude tumor-bearing mice

[0192] 3.4 SPECT / CT imaging

[0193] Towards 177 The three Lu-labeled molecules (JYT2-401, FAP2286, and JY2-011 (PNT6555)) were added with an appropriate amount of PBS buffer solution to prepare the test sample (pH ~5.5-6). After mixing evenly, 100 μL was drawn with an insulin syringe. Each mouse was injected with only ~400 μCi (1-2 nmol) of the molecule, and the measured activities were177 Lu-JYT2-401: 415 μCi, 177 Lu -FAP2286: 435 μCi, JY2-011 (PNT6555): 420 μCi were injected into mice via the tail vein.

[0194] About 48 hours after administration, 180 μL of 1% sodium pentobarbital solution was drawn up by a syringe and intraperitoneally administered into the mouse to anesthetize the mouse. The anesthetized mouse was fixed to the SPECT / CT instrument bed, and the SPECT / CT was scanned after CT positioning.

[0195] After the scan is completed, the data is reconstructed and the mouse SPECT data is circled with ROI using software to obtain the radioactivity distribution %ID / g of tumor organs and tissues.

[0196] Results Fig.18 SPECT / CT imaging was performed at 1h, 2h, 4h, 8h, 24h, 48h, and 72h, and the radioactive signals (%ID / cc) in the mouse tumors were circled. The results showed 177 Lu-JYT2-401 was retained in the tumor for a long time, and the maximum tumor uptake was maintained at ~40%ID / cc. The average value of tumor uptake was comparable to the biodistribution data in Section 3.3. After 48 h, it was ~15%ID / cc and a significant decrease was observed with prolonged time.

[0197] Results Fig.19 .contrast 177 Lu-JYT2-401 and control group 177 Lu-FAP2286, 177 The MIP image of SPECT imaging 48 hours after Lu-PNT6555 injection and the maximum tumor uptake in SPECT images were compared. 177 The maximum uptake of Lu-JYT2-401 was significantly higher than 177 Lu-FAP2286, 177 Lu-PNT6555. Since the molecule undergoing clinical trials for treatment is 177 Lu-FAP2286, and 177 Lu-FAP2286 tumor uptake was also higher than 177 Lu-PNT6555, so the subsequent comparison 177 Lu-JYT2-401 and 177 Efficacy study of Lu-FAP2286.

[0198] 3.5 Pharmacological efficacy studies

[0199] The purpose of this study was to evaluate the efficacy of a single injection by assessing tumor growth delay.177 The therapeutic efficacy of Lu-JTY2-401.

[0200] Available in 1 concentration 177 Lu-JTY2-401 and 177 Lu-FAP2286 was prepared for injection (100 μL / mouse), and the injected dose was determined using a radioactivity meter (calibrated by CAPINTEC).

[0201] Provided as described in Section 3.1 above 177 Lu-JTY2-401 and 177 Lu-FAP2286. The following therapeutic compositions were prepared: 1. Vehicle (Normal saline, 100 μL) per

[0202] 2. 177 Lu-JTY2-401 15MBq (100 μL) each

[0203] 3. 177 Lu-FAP2286 15MBq (100 μL) each

[0204] A total of 15 HEK293 human embryonic kidney cell Balb / c nude tumor-bearing mice were injected with a single tail vein injection 177 Lu-JYT2-401 and 177 Lu-FAP2286 injection. Throughout the study, mice were examined weekly for health, including body weight measurements. Tumor growth was monitored weekly by caliper measurements (tumor volume = length × width 2 × 0.5). Study endpoints included tumors of any dimension > 2 cm, tumor ulceration, mouse moribundity, and weight loss > 15% from the last measurement. Mice were housed in cages of 5 with ad libitum access to food and water at an ambient temperature of 20°C, 40%-50% humidity, and a 12-hour light / 12-hour dark cycle. The injected dose was determined using a radioactivity meter (calibrated by CAPINTEC). Tumor growth was monitored weekly by caliper measurements, and mouse survival was followed.

[0205] Results: Data collected as tumor volume Fig. 20 and survival analysis Fig.21 .

[0206] By comparing tumor volume, survival rate and TGI, 177 Lu-JTY2-401 tumor suppression is superior to 177 Lu-FAP2286, survival time is also longer than 177 Lu-FAP2286 lasts longer.

[0207] Table 8

[0208] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent replacements for some of the technical features therein. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.

Claims

1. A compound represented by formula (I) or a pharmaceutically acceptable tautomer, racemate, hydrate, solvate or salt thereof, It is characterized in that The structural formula of the compound represented by formula (I) is: (I); in, is a nitrogen-containing 4-10-membered cyclic compound, wherein n is any integer from 0 to 6; R 2 , R 3 , R 4 are independently selected from -H, -F, -Cl, -Br, -I, -C 1-6 Alkyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, alkenyl, heteroalkenyl, cycloalkenyl, cycloheteroalkenyl, alkynyl, aryl or -C 1-6 Arylalkyl, the -C 1-6 Each of the alkyl groups is optionally substituted with 1 to 3 substituents selected from -OH, oxygen, halogen; R 5 is a 1-naphthyl moiety or a 5- to 10-membered N-containing aromatic or non-aromatic monocyclic or bicyclic heterocyclic ring, which optionally further contains 1, 2 or 3 heteroatoms selected from O, N and S; L represents a bond or a linker; R 6 represents any of the following functional groups: an optical dye, a photodynamic therapy agent, a radioimaging agent, a radiotherapeutic agent, a chemotherapeutic agent, an antifibrotic agent, or an anticancer agent; Preferably, the nitrogen-containing cyclic compound is a group of a fibroblast activation protein ligand; Preferably, R 1 Selected from -H, -CN, -F, -F 2 、-B(OH) 2 , -C(O)-alkyl, -C(O)-aryl-, -C=CC(O)-aryl, -C=CS(O) 2 -Aryl, -CO 2 H, -SO 3 H, -SO 2 NH 2 、-SO 2 F, -CH 2 SO 2 F.-PO 3 H 2 , cyclic ether group or 5-tetrazolyl group; Preferably, Selected from .

2. The compound of formula (I) according to claim 1 or its pharmaceutically acceptable tautomer, racemate, hydrate, solvate or salt, It is characterized in that In the general formula (I), Select from any of the following structural formulas: ; Among them, R 8 , R 9 , R 10 There is no or independently 1 or 2 heteroatoms selected from O, N and S; Preferably, Select from any of the following structural formulas: ; Preferably, Select from any of the following structural formulas: 。 3. The compound of formula (I) according to claim 1 or 2, or a pharmaceutically acceptable tautomer, racemate, hydrate, solvate or salt thereof, It is characterized in that L is the intermediate linking fragment between the active fragment and the metal complex; Preferably, L comprises one or more linker groups, each linker group being independently selected from (alkylene), (heteroalkylene), (heterocycloalkylene), heteroaryl, aryl, alkoxy, thioether, disulfide, carboxylic acid, anhydride, carbonate, carbamate, thioether, sugar, peptide, polyethylene glycol, amide or ester; Preferably, L independently or in any combination thereof comprises at least one linker group having the following structure: ; Wherein, n is any integer from 1 to 10; More preferably, L comprises one or more of the following linker groups: ; Among them, R 7 Selected from -H, -C 1-6 Alkyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, alkenyl, heteroalkenyl, cycloalkenyl, cycloheteroalkenyl, alkynyl, aryl or -C 1-6 Arylalkyl, the -C 1-6 Each of the alkyl groups is optionally substituted by 1 to 3 substituents selected from -OH, oxygen, and halogen; n is any integer from 1 to 10; Preferably, R 6 It is a ligand part, which is a chelating agent that forms a complex with a divalent or trivalent metal cation; preferably, the chelating agent is selected from 1,4,7,10-tetraazacyclododecane-N,N',N,N'-tetraacetic acid, ethylenediaminetetraacetic acid, 1,4,7-triazacyclononane-1,4,7-triacetic acid, triethylenetetramine, iminodiacetic acid, diethylenetriamine-N,N,N',N',N-pentaacetic acid, bis-(carboxymethylimidazole)glycine or 6-hydrazinopyridine-3-carboxylic acid; Or, R 6 is a ligand moiety, wherein the ligand moiety is a non-radioactive isotope, a radioactive isotope, a radiopharmaceutical or a combination thereof; preferably, the radioactive isotope is selected from an alpha-emitting isotope, a beta-emitting isotope, a gamma-emitting isotope, an Auger electron-emitting isotope, an X-ray-emitting isotope, for example 18 F. 18 F-Al, 51 Cr, 67 Ga, 68 Ga, 111 In, 99m Tc, 186 Re, 188 Re, 139 La, 140 La, 175 Yb, 153 Sm, 166 Ho, 88 Y. 90 Y. 149 Pm, 165 Dy, 169 2. 177 Lu, 47 Sc, 142 Pr, 159 Gd, 212 Bi, 213 Bi, 72 As, 72 Se, 97 Such as 109 Pd, 105 Rh, 101m Rh, 119 Sb, 128 8. 123 I. 124 I. 131 I. 149 Tb, 152 Tb, 155 Tb, 161 Tb, 197 Hg, 211 At 151 Eu, 153 Eu, 169 Eu, 201 Tl, 203 Pb, 212 Pb, 64 Cu, 67 Cu, 188 Re, 186 Re, 198 Au, 225 Ac, 227 Th and 199 Ag; Or, R 6 is a ligand moiety selected from the group consisting of fluorescent dyes of the following classes: xanthines, acridines, oxazines, cyanines, styryl dyes, coumarins, porphyrins, metal ligand-complexes, fluorescent proteins, nanocrystals, perylenes, boron dipyrromethenes, and phthalocyanines, and conjugates and combinations of these classes of dyes; Or, R 6 The contrast agent comprises or consists of a paramagnetic agent; preferably, the paramagnetic agent comprises or consists of paramagnetic nanoparticles.

4. The compound of formula (I) according to any one of claims 1 to 3 or a pharmaceutically acceptable tautomer, racemate, hydrate, solvate or salt thereof, It is characterized in that Has any of the following structural formulas: 。 5. A pharmaceutical composition comprising the compound of formula (I) according to any one of claims 1 to 4 or a pharmaceutically acceptable tautomer, racemate, hydrate, solvate or salt thereof; preferably, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier and / or excipient.

6. A targeted fibroblast activation protein inhibitor or binder, It is characterized in that Including the compound represented by formula (I) according to any one of claims 1 to 4 or its pharmaceutically acceptable tautomer, racemate, hydrate, solvate or salt, or the pharmaceutical composition according to claim 5.

7. A kit comprising the compound of formula (I) according to any one of claims 1 to 4 or its pharmaceutically acceptable tautomer, racemate, hydrate, solvate or salt or the pharmaceutical composition according to claim 5; and instructions for diagnosing or treating a disease.

8. Use of the compound of formula (I) according to any one of claims 1 to 4 or its pharmaceutically acceptable tautomer, racemate, hydrate, solvate or salt or the pharmaceutical composition according to claim 5 for preparing drugs for diagnosing and / or treating diseases; Preferably, the disease includes a disease characterized by overexpression of fibroblast activation protein in an animal or human subject; further preferably, the disease is selected from cancer, chronic inflammation, atherosclerosis, fibrosis, tissue remodeling and scar disease; more preferably, the cancer is selected from small intestine cancer, head and neck cancer, hepatocellular carcinoma, hypopharyngeal cancer, nasopharyngeal carcinoma, myeloma cells, cholangiocarcinoma, clear cell renal carcinoma, neuroendocrine tumors, carcinogenic osteomalacia, sarcoma, primary unknown cancer, thymic carcinoma, glioma, glioma, astrocytoma, cervical cancer, eye cancer, rectal cancer, colon cancer , cervical cancer, prostate cancer, breast cancer, bladder cancer, oral cancer, stomach cancer, liver cancer, pancreatic cancer, lung cancer, uterine cancer, ovarian cancer, testicular cancer, kidney cancer, brain cancer, central nervous system cancer, pharyngeal cancer, skin melanoma, acute lymphocytic leukemia, acute myeloid leukemia, Ewing's sarcoma, Kaposi's sarcoma, basal cell carcinoma and squamous cell carcinoma, small cell lung cancer, choriocarcinoma, rhabdomyosarcoma, angiosarcoma, hemangioendothelioma, Wilms tumor, neuroblastoma, esophageal cancer, laryngeal cancer, lymphoma, neurofibroma, tuberous sclerosis, hemangioma or lymphoma.

9. A tumor therapeutic agent, It is characterized in that A compound represented by formula (I) according to any one of claims 1 to 4 or a pharmaceutically acceptable tautomer, racemate, hydrate, solvate or salt thereof, or a pharmaceutical composition according to claim 5.

10. A tumor imaging agent, It is characterized in that A compound represented by formula (I) according to any one of claims 1 to 4 or a pharmaceutically acceptable tautomer, racemate, hydrate, solvate or salt thereof, or a pharmaceutical composition according to claim 5.

Citation Information

Patent Citations

  • Inhibitors of fibroblast activation protein alpha

    CN101247799A

  • FAP inhibitor

    CN111699181A

  • Compound targeting FAP (fibroblast activating protein) as well as preparation method and application of compound

    CN115260160A

  • FAP Inhibitors

    EP1760076A1

Cited By

  • Targeted-binding fibrocyte-activated protein polymer compound and application thereof

    CN119192214A

  • A multimeric compound targeting and binding to fibroblast activation protein and its application

    CN119192214B

  • Bicyclo [1.1. 1] pentane compound of targeted binding fibrocyte activating protein and application of bicyclo [1.1. 1] pentane compound

    CN119390720A

  • Compound targeting fibroblast activating protein and application thereof

    CN120590466A

  • Fibroblast activating protein targeted multivalent radioactive probe as well as preparation method and application thereof

    CN121609752A